In this line, we found that Glabridin markedly inhibited the expression of major signalling pathways such as AMPK, C‐MYC, AKT and NOTCH (Supplementary Figure S7A–P) associated with metabolic reprogramming in cancer cells. Here, MYC is linked to cancer.